Treatment with carfilzomib. Should these patients be admitted in the Intensive Care Unit?

Med Intensiva (Engl Ed). 2018 Jan-Feb;42(1):60-62. doi: 10.1016/j.medin.2017.02.004. Epub 2017 Mar 16.
[Article in English, Spanish]
No abstract available

Publication types

  • Case Reports
  • Letter
  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Combined Modality Therapy
  • Critical Care*
  • Dexamethasone / administration & dosage
  • Fatal Outcome
  • Heart / drug effects
  • Heart Arrest / chemically induced*
  • Heart Arrest / therapy
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Lenalidomide / administration & dosage
  • Male
  • Middle Aged
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / therapy
  • Oligopeptides / administration & dosage
  • Oligopeptides / adverse effects*
  • Protease Inhibitors / administration & dosage
  • Protease Inhibitors / adverse effects*
  • Pulmonary Edema / chemically induced*
  • Pulmonary Edema / therapy
  • Recurrence
  • Salvage Therapy
  • Transplantation, Autologous

Substances

  • Oligopeptides
  • Protease Inhibitors
  • carfilzomib
  • Dexamethasone
  • Lenalidomide